Recent Finacing
Recent Raise
CytomX develops protease‑activated masked antibodies (Probodies) and Probody drug conjugates inert in healthy tissue and activated in tumor microenvironments to enable oncology immunotherapies, bispecifics, and engineered T‑cell therapies.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors